Laidlaw analyst Francois Brisebois initiated Tiziana Therapeutics with a Buy and $17 price target saying the main value driver consists of Foralumab in development as a potential treatment for large unmet medical needs such as NASH. While Foralumab remains in Phase 1, Brisebois sees their fully human oral anti-CD3 mAb as relatively de-risked as fully murine OKT3 showed encouraging immunological trends in a previous Phase 2 trial in NASH. The analyst said 2019 is setting up as a catalyst year with potential data readouts in both their oral and intranasal Foralumab trials as well as their Phase 2a monotherapy.

Tiziana Life Sciences announced additional positive clinical results from its intermediate sized Expanded Access Program, EAP, for non-active secondary progressive multiple sclerosis patients. The data demonstrate multiple improvements in foralumab-treated patients, with 70% showing an improvement in fatigue after six months of follow-up. Fatigue is a debilitating symptom for many MS patients and is measured by the Modified Fatigue Impact Scale, MFIS. Gabriele Cerrone, Chairman, acting CEO and founder of Tiziana Life Sciences, commented "Fatigue is a pervasive and challenging symptom for individuals living with MS, impacting their daily lives in profound ways. The clinically meaningful improvement in fatigue levels seen in seven out of ten patients, as well as the stabilization or improvements in other key clinical outcome measures that were seen in all patients, underscores the potential of Tiziana's investigational therapy to address this critical unmet need."